Please login to the form below

Medius Deal Watch table for February 2015

The top major pharma mergers, acquisitions and collaborations during the month were led by the Pfizer/Hospira and Salix/Valeant deals

Whilst not quite matching January's mega-deal tally February brought home a very respectable score of three deals with values in excess of $1bn. Within the top 20 deals by value for the month the prevailing mood was buy, buy, buy be it wholesale acquisition of companies (6), business units (2) or single assets (2). [Read the month's pharma deal commentary in full.]

Here Medius present a run down of the month's biggest mergers, acquisitions and collaborations from across the sector.

Licensor Acquired / Licensee Acquirer	Product / Technology	Deal Type	Headline $m
Hospira/ Pfizer	Injectable biosimilar drugs and infusion technologies	Corporate acquisition	17,000
Salix Pharmaceuticals/ Valeant Pharmaceuticals	GI products	Corporate acquisition	14,500
Flexus Biosciences/ BMS	F001287, IDO1 inhibitor + IDO/TDO discovery programme - immuno-oncology	Corporate acquisition	1,250
Voyager Therapeutics/ Sanofi (Genzyme)	Gene therapy - Parkinson's disease, Friedreich's ataxia and Huntington's disease	Collaboration - discover, develop, commercialise	845
Famy Care/ Mylan	Female healthcare businesse	Acquisition - business units	800
*Actavis/ AstraZeneca	Respiratory medicines	Acquisition - business unit	700
NGM Biopharmaceuticals/ Merck & Co	NP201 + other preclinical candidates - diabetes, obesity, non-alcoholic steatohepatitis (NASH)	Collaboration - discover, develop, commercialise	450
Heptares Therapeutics/ Sosei Group	Novel G protein-coupled receptor targeted drug candidates - Alzheimer's disease, metabolic disease, schizophrenia, migraine etc	Corporate acquisition	400
Dendreon/ Valeant Pharmaceuticals	PROVENGE® (sipuleucel-T) and other assets - prostate cancer	Corporate acquisition	400
Shanxi Powerdone/ Harbin Gloria Pharma	Chemical drug and compound preparation manufacturing	Majority acquisition	380
Pfenex/ Hospira	PF582 - LUCENTIS® biosimilar candidate - wet age-related macular degeneration, diabetic macular oedema	Collaboration - develop and commercialise	342
Rigel Pharmaceuticals/ BMS	Small molecule TGF beta receptor kinase inhibitors - immuno-oncology	Collaboration - discover, develop, commercialise	339
Theravance/ Mylan	TD-4208- a novel once-daily nebulised long-acting muscarinic antagonist (LAMA) - COPD	Collaboration - develop and commercialise	265
Meritage Pharma/ Shire	Phase 3-ready oral budesonide suspension (OBS) - eosinophilic esophagitis (EoE)	Corporate acquisition	245††
Vernalis/ Not disclosed	Adenosine receptor antagonist programme, including the lead drug candidate, V81444	Licence	201
GlycoVaxyn/ GSK	Conjugation platform plus early stage vaccines against bacterial infections such as pneumonia, Pseudomonas, S. aureus and Shigellosis	Corporate acquisition	190
**Amarin/ Eddingpharm	VASCEPA® (icosapent ethyl) - triglyceride level reduction	Collaboration - develop and commercialise	169
Orca Pharmaceuticals/ AstraZeneca	Retinoic acid-related orphan nuclear receptor gamma (RORγ) inhibitors - autoimmune diseases	Collaboration - discover, develop, commercialise	122.5
***Neutec/ Takeda	Portfolio of 13 drugs - GI, respiratory, metabolic and musculoskeletal	Asset acquisition - products	121
†Eagle Pharmaceuticals/ Teva	EP-3102 - bendamustine hydrochloride rapid infusion product - CLL, indolent B-cell NHL	Licence - distribute and promote	120

All deals global unless otherwise stated:
* US and Canada
** China, Hong Kong, Macao Special Administrative Regions, Taiwan
*** Turkey
† US
†† Financial details source - Viropharma's 2013 Consolidated Financial Statement

Abbreviations:
IDO, Indoleamine-2, 3-dioxygenase; TDO, Tryptophan-2,3- dioxygenase
COPD, chronic obstructive pulmonary disease
CLL, chronic lymphocytic leukaemia; NHL, indolent non-Hodgkin lymphoma